196 related articles for article (PubMed ID: 17461929)
1. Effect of the anti-factor Xa and anti-factor IIa activities of low-molecular-weight heparins upon the phases of thrombin generation.
Gerotziafas GT; Petropoulou AD; Verdy E; Samama MM; Elalamy I
J Thromb Haemost; 2007 May; 5(5):955-62. PubMed ID: 17461929
[TBL] [Abstract][Full Text] [Related]
2. Effect of low molecular weight heparins and fondaparinux upon thrombin generation triggered by human pancreatic cancer cells BXPC3.
Gerotziafas GT; Galea V; Mbemba E; Sassi M; Roman MP; Khaterchi A; van Dreden P; Japcowitz M; Lotz JP; Bernaudin JF; Fareed J; Hatmi M; Elalamy I
Curr Vasc Pharmacol; 2014; 12(6):893-902. PubMed ID: 22724467
[TBL] [Abstract][Full Text] [Related]
3. The Antithrombotic Potential of Tinzaparin and Enoxaparin Upon Thrombin Generation Triggered In Vitro by Human Ovarian Cancer Cells IGROV1.
Sassi M; Chakroun T; Mbemba E; Van Dreden P; Elalamy I; Larsen AK; Gerotziafas GT
Clin Appl Thromb Hemost; 2017 Mar; 23(2):155-163. PubMed ID: 27609342
[TBL] [Abstract][Full Text] [Related]
4. Effects of nadroparin, enoxaparin, and unfractionated heparin on endogenous factor Xa and IIa formation and on thrombelastometry profiles.
Cvirn G; Wagner T; Juergens G; Koestenberger M
Blood Coagul Fibrinolysis; 2009 Jan; 20(1):71-7. PubMed ID: 20339323
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the effect of fondaparinux and enoxaparin on thrombin generation during in-vitro clotting of whole blood and platelet-rich plasma.
Gerotziafas GT; Depasse F; Chakroun T; Van Dreden P; Samama MM; Elalamy I
Blood Coagul Fibrinolysis; 2004 Mar; 15(2):149-56. PubMed ID: 15091002
[TBL] [Abstract][Full Text] [Related]
6. Effects of nadroparin, enoxaparin, and unfractionated heparin on endogenous formation of factor Xa and IIa and on thrombelastometry profiles in cord versus adult blood.
Cvirn G; Hoerl G; Tafeit E; Heinl N; Wodrig K; Wagner T; Koestenberger M; Juergens G
Neonatology; 2011; 100(1):23-31. PubMed ID: 21150227
[TBL] [Abstract][Full Text] [Related]
7. A rationally designed heparin, M118, has anticoagulant activity similar to unfractionated heparin and different from Lovenox in a cell-based model of thrombin generation.
Volovyk Z; Monroe DM; Qi Y; Becker R; Hoffman M
J Thromb Thrombolysis; 2009 Aug; 28(2):132-9. PubMed ID: 19543696
[TBL] [Abstract][Full Text] [Related]
8. Antithrombotic activity and its relationship to in vitro anticoagulant effects.
Gray E; Padilla A; Barrowcliffe TW
Haemostasis; 1993 Mar; 23 Suppl 1():99-102. PubMed ID: 8388358
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of thrombin generation by heparin and low molecular weight (LMW) heparins in the absence and presence of platelet factor 4 (PF4).
Padilla A; Gray E; Pepper DS; Barrowcliffe TW
Br J Haematol; 1992 Oct; 82(2):406-13. PubMed ID: 1329921
[TBL] [Abstract][Full Text] [Related]
10. Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications.
Maddineni J; Walenga JM; Jeske WP; Hoppensteadt DA; Fareed J; Wahi R; Bick RL
Clin Appl Thromb Hemost; 2006 Jul; 12(3):267-76. PubMed ID: 16959680
[TBL] [Abstract][Full Text] [Related]
11. Monitoring low molecular weight heparins at therapeutic levels: dose-responses of, and correlations and differences between aPTT, anti-factor Xa and thrombin generation assays.
Thomas O; Lybeck E; Strandberg K; Tynngård N; Schött U
PLoS One; 2015; 10(1):e0116835. PubMed ID: 25625201
[TBL] [Abstract][Full Text] [Related]
12. Thromboprophylaxis following caesarean section--a comparison of the antithrombotic properties of three low molecular weight heparins--dalteparin, enoxaparin and tinzaparin.
Ellison J; Thomson AJ; Conkie JA; McCall F; Walker D; Greer A
Thromb Haemost; 2001 Dec; 86(6):1374-8. PubMed ID: 11776302
[TBL] [Abstract][Full Text] [Related]
13. Involvement of the extrinsic pathway in the activities of low molecular weight heparins.
Norrheim L; Abildgaard U; Larsen ML; Lindahl AK
Thromb Res Suppl; 1991; 14():19-27. PubMed ID: 1658967
[TBL] [Abstract][Full Text] [Related]
14. Blocking inhibition of prothrombinase by tissue factor pathway inhibitor alpha: a procoagulant property of heparins.
Wood JP; Baumann Kreuziger LM; Desai UR; Mast AE
Br J Haematol; 2016 Oct; 175(1):123-32. PubMed ID: 27301751
[TBL] [Abstract][Full Text] [Related]
15. Influence of different anticoagulant agents on fibrinopeptide a generation.
Tobu M; Iqbal O; Messmore HL; Ma Q; Hoppensteadt DA; Fareed J
Clin Appl Thromb Hemost; 2003 Oct; 9(4):273-92. PubMed ID: 14653437
[TBL] [Abstract][Full Text] [Related]
16. In vitro comparison of the novel, dual-acting FIIa/FXa-inhibitor EP217609C101, unfractionated heparin, enoxaparin, and fondaparinux in preventing cardiac catheter thrombosis.
Kaeberich A; Raaz U; Vogt A; Maedgefessel L; Neuhart E; Krezel C; Drouget L; Hauroeder B; Buerke M; Werdan K; Schlitt A
J Thromb Thrombolysis; 2014; 37(2):118-30. PubMed ID: 23821043
[TBL] [Abstract][Full Text] [Related]
17. In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux.
Samama MM; Mendell J; Guinet C; Le Flem L; Kunitada S
Thromb Res; 2012 Apr; 129(4):e77-82. PubMed ID: 21851967
[TBL] [Abstract][Full Text] [Related]
18. Comparative efficacy of different low-molecular-weight heparins (LMWHs) and drug interactions with LMWH: implications for management of vascular disorders.
Mousa SA
Semin Thromb Hemost; 2000; 26 Suppl 1():39-46. PubMed ID: 11011805
[TBL] [Abstract][Full Text] [Related]
19. From unfractionated heparin to pentasaccharide: Paradigm of rigorous science growing in the understanding of the in vivo thrombin generation.
Spadarella G; Di Minno A; Donati MB; Mormile M; Ventre I; Di Minno G
Blood Rev; 2020 Jan; 39():100613. PubMed ID: 31471127
[TBL] [Abstract][Full Text] [Related]
20. Determination of the levels of unfractionated and low-molecular-weight heparins in plasma: their effect on thrombin-mediated feedback reactions in vivo. Preliminary results after subcutaneous injection.
Hemker HC; Béguin S; Bendetowicz AV; Wielders S
Haemostasis; 1991; 21(4):258-72. PubMed ID: 1665467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]